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Abstract
Background: One controversial source of infection for hepatitis C virus (HCV) involves the
sharing of contaminated implements, such as straws or spoons, used to nasally inhale cocaine and
other powdered drugs. An essential precondition for this mode of transmission is the presence of
HCV in the nasal secretions of intranasal drug users.
Methods: Blood and nasal secretion samples were collected from five plasma-positive chronic
intranasal drug users and tested for HCV RNA using RT-PCR.
Results: HCV was detected in all five blood samples and in the nasal secretions of the subject with
the highest serum viral load.
Conclusions: This study is the first to demonstrate the presence of HCV in nasal secretions. This
finding has implications for potential transmission of HCV through contact with contaminated nasal
secretions.
Background
Hepatitis C virus (HCV) is a major cause of liver-related
morbidity and mortality worldwide, with an estimated
global prevalence of 170 million chronic infections. HCV-
induced liver disease is the most common indication for
liver transplantation and it has emerged as a leading cause
of death among hospitalized HIV-infected patients treated
during the HAART era [1]. Transmission of HCV is known
to occur through contact with contaminated blood, most
notably in the context of injection drug use, transfusion of
blood products prior to 1992, chronic hemodialysis,
occupational exposure to blood, and nosocomial and
perinatal exposure. In addition, several studies have
reported low levels of suspected sexual and household
transmission of HCV [2].
Although much is known about the routes of HCV trans-
mission, nearly 15% of infected individuals report no
identifiable source of exposure. Unexplained cases are
particularly high among drug-users who have no history
of injection risk and no other identifiable risk factors [3].
One hypothesis that might account for the high number
of unexplained HCV infections among noninjection drug-
users was proposed by researchers at the US National
Institutes of Health (NIH), who identified intranasal
cocaine use as a significant risk factor for HCV among
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volunteer blood donors [4]. They reasoned that HCV
might be transmitted through contaminated implements,
such as straws or spoons, that are commonly used to
nasally inhale powdered drugs, including heroin, cocaine,
and methamphetamines. Chronic nasal inhalation of
these substances (including the adulterants they contain)
can cause tissue deterioration and bleeding of nasal mem-
branes. Implements inserted into an eroded nasal cavity
may come into contact with HCV-infected mucus or
blood, which may then be transmitted to an uninfected
individual sharing the same implement. The debate
regarding this potential mode of transmission intensified
when the National Heart, Lung and Blood Institute
(NHLBI) Retrovirus Epidemiology Donor Study (REDS)
was unable to confirm intranasal drug inhalation as an
independent risk factor for HCV [5]. These conflicting
reports prompted the American Association of Blood
Banks (AABB) to add, and then shortly thereafter remove,
intranasal cocaine use from their list of criteria used to
screen potential blood donors. A subsequent review of the
literature found serious methodological limitations with
both the NIH and NHLBI/REDS studies [6]. Although
HCV has been detected in the saliva, semen, and other
nonserological fluids of some plasma-positive patients
[7], no virological studies have been undertaken to deter-
mine whether HCV is present in the nasal secretions of
intranasal drug users, a necessary precondition for inter-
nasal viral transmission. Here, we report preliminary find-
ings on the detection of HCV RNA in the nasal secretions
of plasma-positive chronic drug sniffers.
Methods
Study subjects
Five patients were recruited for the study from the Boriken
Neighborhood Health Center in East Harlem, New York
City. The subjects were selected from consecutive clinic
patients who had previously tested HCV seropositive and
who reported a history of intranasal drug use. The first
four subjects were HCV antibody reactive and seropositive
on quantitative PCR; the fifth subject tested seropositive
for HCV antibodies but HCV PCR negative (<600 copies/
mL). All subjects were male between 46 to 56 years of age
and HIV-1 seropositive. Table 1 presents patient serologi-
cal indicators for hepatitis C, as well as hepatitis B, HIV-1,
ALT levels, and liver biopsy results.
Table 1: Study subject serology results and indicators
Subjects HCV PCR Copies per ml 
(Date of test)
HepBsAb HepBsAg HepBcAb HIV Viral Load 
Copies per ml
ALT U/L Liver Biopsy
1 10,800,000
(11/99)
Neg Neg Pos 633
(12/03)
32 (12/03) Activity: Mild Stage 2 of 4
(08/00)
34,500,000 IU 
(12/03)
270,000
(01/03)
2 8,360,000
(09/99)
Neg Neg Pos 180,000
(10/03)
16
(02/04)
Not done due to bleeding 
diathesis
96,000
(02/04)
16
(10/03)
3 1,320,000
(10/03)
Pos Neg Pos 16,900
(02/04)
110
(10/03)
Grade 2/3 of 4 Stage 2/3 of 4 
(11/03)
182
(02/04)
4 234,000
(12/02)
Neg Neg Neg 72,031
(12/02)
37
(12/03)
Grade 1 of 4 Stage 1 of 4
(11/03)
<50
(12/03)
5 <600 Neg Neg Pos 212,000
(10/03)
41
(10/03)
Not done
104
(04/04)
HCV = hepatitis C virus; HepB = hepatitis B; s = surface; c = core; Ab = antibody; Ag = antigen; HIV = human immunodeficiency virus; ALT = 
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Biological samples
Blood samples were collected from each subject using
standard clinical procedures for quantitative HCV RNA
testing. Nasal secretion samples were obtained using a
nasal swab technique. Samples from nasal swabs were
placed into sterile tubes containing 1 mL of TRIzol reagent
(Glibco BRL) and stored at -70°C. Study protocols were
approved by an Institutional Review Board and all study
participants provided voluntary informed consent.
Isolation and detection of HCV RNA
HCV RNA was isolated from serum samples by QIAamp
MinElute column (Qiagen) based on manufacturer's pro-
tocol, and from nasal secretions by TRIzol (Gibco BRL)
based on established protocols [8]. Briefly, nasal swab
samples were subjected to vortexing for 30 s and incu-
bated at 21°C for 5 min to permit the complete dissocia-
tion of nucleoprotein complexes. Subsequently, TRIzol
solution was transferred into a new Eppendorf tube,
mixed with 0.2 mL of chloroform, mixed vigorously for
15 s, and incubated at 21°C for 3 min. RNA extraction
and phase separation was obtained by centrifugation at 12
000 × g for 15 min at 4°C. The aqueous phase was trans-
ferred into a new Eppendorf tube and mixed with 1 µL of
RNase-free glycogen (New England Biolabs). RNA was
precipitated with 0.5 mL of isopropyl alcohol for 10 min
at 21°C followed by centrifugation at 12 000 × g for 10
min at 4°C and washed in 75% ethanol. RNA pellets were
resuspended in 10 µL of RNase-free water.
Detection of HCV RNA was performed by RT-PCR. The
first strand cDNA was synthesized by Superscript™ First
Strand cDNA Synthesis kit (Invitrogen) using gene-spe-
cific downstream primers targeting the HCV p22 core
region [9] with minor modification of the upstream
primer (406(m)5'-TAGACCGGTGCACCATGAGC-3').
HCV cDNA was amplified by PCR through 40 cycles of
denaturation (94°C-1 min), annealing (55°C-1 min) and
elongation (72°C-1 min). Subsequently, PCR products
were resolved through 1% agarose gel electrophoresis,
hybridized to 32P-labeled internal probe (5'-AGGAA-
GACTTCCGAGCGGTCG CAA-3'), and exposed to Kodak
film.
Results and discussion
Previous studies have demonstrated the presence of HCV
in a wide variety of nonserological fluids [7,10]; for
instance, HCV has been detected in about 50% of saliva
samples from plasma-positive individuals [11]. We rea-
soned that HCV might be present in nasal secretions at a
similar prevalence and would therefore be detectable
among a relatively small sample of viremic patients. Five
consecutive plasma-positive clinic patients were selected
for study and each contributed blood and nasal secretion
samples for HCV RT-PCR analysis.
The RT-PCR results confirmed the presence of HCV in the
blood of all five subjects. The highest serum concentra-
tions of viral RNA were detected in subjects 1 and 2 and
the lowest in subject 5 (see Fig. 1); these findings were
consistent with patient record viral loads. It is noteworthy
that our assay detected HCV RNA in the serum of subject
5 (previously below the level of detection with commer-
cially available assays), indicating low-level viremia, and
verifying the high sensitivity of our analysis.
HCV RNA detection from serum and nasal secretions of five intranasal drug users Figure 1
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Significantly, HCV particles were also detected from the
nasal secretions of subject 1 (Fig. 1). This subject, a 56-
year-old African-American male, also exhibited the high-
est HCV serum viral load (34 500 000 IU/mL). HCV was
not detected in the nasal secretions of the other four study
subjects. This finding represents the first demonstration of
the presence of HCV RNA in nasal secretions.
Great care was taken to avoid sample contamination dur-
ing all phases of the study. Blood samples of known serol-
ogy were collected from each of the five subjects and
tested for HCV RNA to confirm the validity of our labora-
tory procedures. The TRIzol assay used on the nasal secre-
tion samples in this study has been shown to be effective
for RNA isolation with a variety of other nonserological
samples [11,12].
Conclusions
To our knowledge, this is the first study to demonstrate
the presence of HCV in the nasal secretions of an intrana-
sal drug-user. While this finding does not confirm interna-
sal viral transmission, it does lend virological support to
previous indications that intranasal drug use poses a risk
by confirming an important precondition for this route of
infection. Additionally, detection of HCV in nasal secre-
tions advances the debate regarding potential iatrogenic
and nosocomial transmission of HCV in the context of
ENT practices. More research involving larger samples is
needed to replicate our results, provide an accurate esti-
mate of HCV prevalence in the nasal secretions of plasma-
positive patients, and determine whether intranasal HCV
derives from blood in the nasal cavity or directly from
nasal secretions. Future research should also address
whether the presence HCV in the nasal cavity affects the
progression of upper respiratory infections such as influ-
enza, rhinovirus, adenovirus, coronavirus, and severe
acute respiratory virus.
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